ALEXANDRIA, Va. / Jul 17, 2024 / Business Wire / Spok Holdings, Inc. (NASDAQ: SPOK), a global leader in healthcare communications, today announced it will release its second quarter 2024 operating results on Wednesday, July 24, 2024, after the close of the U.S. financial markets.
Management will host a conference call and webcast to discuss these financial results on Wednesday, July 24, 2024, at 5:00 p.m. ET. The presentation is open to all interested parties and may include forward-looking information.
Conference Call Details
Date/Time | Wednesday, July 24, 2024, at 5:00 p.m. ET | |||
Webcast: | ||||
U.S. Toll-Free Dial In: | 877-407-0890 | |||
International Dial In: | +1-201-389-0918 | |||
To access the call, please dial in approximately ten minutes before the start of the call. For those unable to join the live call, an OnDemand version of the webcast will be available following the call under the URL link and on the investor relations website.
About Spok
Spok Holdings, Inc. (NASDAQ: SPOK), headquartered in Alexandria, Virginia, is proud to be a global leader in healthcare communications. We deliver clinical information to care teams when and where it matters most to improve patient outcomes. Top hospitals rely on the Spok Care Connect® platform to enhance workflows for clinicians and support administrative compliance. Our customers send over 70 million messages each month through their Spok® solutions. Spok enables smarter, faster clinical communication.
Spok is a trademark of Spok Holdings, Inc. Spok Care Connect and Spok Mobile are trademarks of Spok, Inc.
| Last Trade: | US$13.90 |
| Daily Change: | 0.07 0.51 |
| Daily Volume: | 98,708 |
| Market Cap: | US$286.340M |
October 29, 2025 July 30, 2025 April 30, 2025 February 26, 2025 October 30, 2024 | |

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load